Skip to main content
Top
Published in: Ophthalmology and Therapy 6/2024

Open Access 25-04-2024 | Xerophthalmia | ORIGINAL RESEARCH

Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK

Authors: Tanner J. Ferguson, Brooke Messer, Nicholas Risbrudt, Seth Stofferahn, Michael Greenwood

Published in: Ophthalmology and Therapy | Issue 6/2024

Login to get access

Abstract

Introduction

The purpose of this study is to evaluate the use of a varenicline solution nasal spray (VNS) for reducing the signs and symptoms of dry eye following laser in situ keratomileusis (LASIK).

Methods

Subjects electing to undergo LASIK were randomized to VNS (study group) or placebo/vehicle (control group) and initiated treatment with the nasal spray twice daily 28 days prior to surgery with continued treatment for 84 days following LASIK. After initiation of treatment, subjects were seen on the day of surgery and postoperatively on Days 1, 7, 28, 84 (3 months) and 168 (6 months). The primary outcome measure was the mean change in NEI-VFQ-25, a 25-item dry eye questionnaire, from baseline to 3 months. The second primary outcome measure was the mean change in corneal fluorescein staining. Secondary outcome measures included evaluation of tear break-up time, Schirmer testing, tear osmolarity and eye dryness score (EDS).

Results

Twenty subjects were enrolled in each group and successfully underwent LASIK. Both groups demonstrated an improvement in the National Eye Institute Visual Function Questionnaire (NEI-VFQ) at 3 months. The study group demonstrated improved corneal staining scores at months 1 and 3. Similarly, the study group demonstrated improvement in tear osmolarity scores versus the placebo group at the same time points. Although the study group was numerically greater than placebo for each time point for both corneal staining and tear osmolarity, the differences were not statistically significant for any primary or secondary outcome measures.

Conclusion

VNS is a dry eye treatment option for patients following LASIK and may have potential benefit for patients hoping to avoid additional topical medications. The results were not statistically significant compared to placebo in this trial, and further investigation of the use of VNS following LASIK in a larger trial would be beneficial.
Literature
1.
go back to reference Gomes JA, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: a review. Ocul Surf. 2019;17(1):9–19.CrossRefPubMed Gomes JA, Santo RM. The impact of dry eye disease treatment on patient satisfaction and quality of life: a review. Ocul Surf. 2019;17(1):9–19.CrossRefPubMed
6.
go back to reference Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154–61.CrossRefPubMed Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154–61.CrossRefPubMed
7.
go back to reference Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022;48(5):623–9.CrossRefPubMed Donaldson K, Parkhurst G, Saenz B, Whitley W, Williamson B, Hovanesian J. Call to action: treating dry eye disease and setting the foundation for successful surgery. J Cataract Refract Surg. 2022;48(5):623–9.CrossRefPubMed
9.
go back to reference Cohen E, Spierer O. Dry eye post-laser-assisted in situ keratomileusis: major review and latest updates. J Ophthalmol. 2018;2018:1–9.CrossRef Cohen E, Spierer O. Dry eye post-laser-assisted in situ keratomileusis: major review and latest updates. J Ophthalmol. 2018;2018:1–9.CrossRef
11.
go back to reference Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease—past, present, and future. Ocul Surf. 2019;17(1):20–7.CrossRefPubMed Dieckmann G, Fregni F, Hamrah P. Neurostimulation in dry eye disease—past, present, and future. Ocul Surf. 2019;17(1):20–7.CrossRefPubMed
Metadata
Title
Varenicline Solution Nasal Spray for the Treatment of Dry Eye Disease Following LASIK
Authors
Tanner J. Ferguson
Brooke Messer
Nicholas Risbrudt
Seth Stofferahn
Michael Greenwood
Publication date
25-04-2024
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 6/2024
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-024-00949-4

Other articles of this Issue 6/2024

Ophthalmology and Therapy 6/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare